Your SlideShare is downloading. ×
Cystic Fibrosis
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Introducing the official SlideShare app

Stunning, full-screen experience for iPhone and Android

Text the download link to your phone

Standard text messaging rates apply

Cystic Fibrosis

2,401
views

Published on

Dr. Maynard's update on Cystic Fibrosis (presented on 12/9/10).

Dr. Maynard's update on Cystic Fibrosis (presented on 12/9/10).

Published in: Health & Medicine

0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
2,401
On Slideshare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
73
Comments
0
Likes
1
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Cystic FibrosisRoy Maynard, M.D.December 9, 2010
  • 2. Objectives for Cystic Fibrosis• Understand the defect involving the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) in the pathogenesis of lung and pancreatic disease in cystic fibrosis patients.• Describe laboratory testing used to confirm a diagnosis of cystic fibrosis.• Recognize the association between nutritional status and lung function in patients with cystic fibrosis.• Name 3 complications of cystic fibrosis.• Understand the rationale for prescribed treatments for pulmonary exacerbations in patients with cystic fibrosis.
  • 3. Respiratory Disease in CF• Clinical Pulmonary Manifestations – Chronic cough, often productive – Wheezing – Recurrent pneumonia – Nasal polyps – Chronic sinusitis – CF pathogen colonization
  • 4. Gastrointestinal Disease in CF• Clinical Gastrointestinal Manifestations – Medonium ileus, DIOS, rectal prolapse – Pancreatic insufficiency, pancreatitis – Cirrhosis, portal hypertension – Speenomegaly – Failure to thrive, malabsorption
  • 5. Physical Feature of Cystic Fibrosis “Clubbing” of the fingers http://en.wikipedia.org/wiki/File:ClubbingCF.JPG Accessed on 11/10/10
  • 6. Genetics• Northern European ancestry• Autosomal recessive• Most common lethal genetic disease in Caucasians• 1/3,000 births• 30,000 individuals in USA• Chromosome 7• Currently 1,820 known mutations
  • 7. Genetics(Autosomal Recessive) www.cfnz.org.nz/about-cystic-fibrosis/ Accessed on 11/10/10
  • 8. Mutations• Multiple types of mutations – Missense (most common 41%) – Frameshift – Splicing – Nonsense – Deletion• Approximately 80% of mutations accounted for in 24 different mutations
  • 9. Newborn Screening for CF• Newborn screening in Minnesota since March, 2006• Screened for in all 50 states of the union• IRT/DNA screen (immunoreactive trypsinogen)• High false positive rate• Prenatal screening and carrier screening available
  • 10. Laboratory• Sweat chloride >60 mEq/liter confirmatory• 40-60 mEq/liter indeterminate• <40 mEq/liter is normal• Other labs – Hypoproteinemia – Decreased calcium levels – Hyponatremia – Increased stool fat
  • 11. Laboratory Diagnosis• Elevated sweat chloride• Newborn screen• Genetic testing• Malabsorption – 15% pancreatic sufficient – 85% pancreatic insufficient
  • 12. Cystic Fibrosis Transmembrane Regulator (CFTR)• CF gene encodes a large single chain polypeptide of 1,480 amino acids (ATP-binding cassette proteins)• Embedded in lipid membrane of epithelial cells, sweat glands, pancreas and lungs• Mediates solute transport, mostly the chloride channel
  • 13. CFTR Proteinhttp://en.wikipedia.org/wiki/File:CFTR.jpg Accessed on 11/10/10
  • 14. Electrolyte Transport Activities of Submucosal GlandsTaussig-Landau, et al. Pediatric Respiratory Medicine. St. Louis: Mosby, Inc., 1999 Accessed on 11/10/10
  • 15. Pathophysiology• Altered airway secretions – Periciliary fluid through which cilia beat – Overlying mucus gel phase http://www.medscape.com/viewarticle/463495_4 (Figure 1B) Accessed on 11/10/10
  • 16. Pathophysiology (continued)• Airway Secretions – Decreased water content – Increased solid content – Higher salt content – Increased submucosal glands and goblet cells and their secretions – Increased amount of dehydrated, viscous secretions that obstruct glands and airways
  • 17. Pathophysiology (continued)• Dilatation of submucosal glands• Mucus plugging of airways• Hypertrophy and hyperplasia of secretory elements• Chronic infections and inflammation• Chronic bronchiolitis• Squamous metaplasia of respiratory epithelium impacts mucociliary clearance• Bronchiectasis• Loss of functional lung parenchyma
  • 18. Pathophysiology (continued)• Airway inflammation – Documented to start in the infant lung despite being normal at birth – Increased neutrophils – Increased neutrophil elastase and other cytokines – Imbalance in anti-inflammatory cytokines – Proteolytic enzymes destroy airway tissues contributing to bronchiectasis
  • 19. Pathophysiology (continued)• Respiratory Tract passengers and pathogens – Pseudomonas aeruginosa – Staphylococcus aureus – Haemophilus influenzae – Aspergillus – Stenotrophomonas maltophilia – Burkholderia cepacia
  • 20. Percent of Patients with Respiratory Infections (by age) http://www.cff.org/UploadedFiles/research/ClinicalResearch/2008-Patient-Registry-Report.pdf Accessed on 11/10/10
  • 21. Complications of Cystic Fibrosis • Hemoptysis • Pneumothorax • Respiratory failure • Cor pulmonale • Severe sinus disease/nasal polyps • Nutritional failure • Infertility • Allergic bronchopulmonary aspergillosis
  • 22. Complications of Cystic Fibrosis (continued)• Cirrhosis with portal hypertension• Pancreatitis• Diabetes• Gallbladder disease• Fibrosing colonopathy• Peptic ulcer disease• Arthropathy/arthritis• Asthma
  • 23. Routine Management• Quarterly visits CF center with pulmonary function testing and nutritional assessment• Annual labs and chest x-rays• High protein diet• Titration of pancreatic enzymes• Fat soluble vitamin supplementation ADEK• Exercise
  • 24. Routine Management (continued)• Daily chest physiotherapy – Huff and cough – Flutter valve – Percussive therapy – High frequency chest wall oscillation• Nebulizer treatments – Inhaled steroids – Beta-agonist – Recombinant DNase – Hypertonic saline – Inhaled antibiotics
  • 25. Main Method of Airway Clearance Therapy (ACT) http://www.cff.org/UploadedFiles/research/ClinicalResearch/2008-Patient-Registry-Report.pdf Accessed on 11/10/10
  • 26. Routine Management (continued) Hill-Rom Vesthttp://www.hill-rom.co.uk/PageFiles/10597/the_vest_w330.jpg Accessed on 11/10/10
  • 27. Routine Management (continued)• Anti-inflammatory therapies – Ibuprofen – Zithromax – Systemic steroids
  • 28. Cystic Fibrosis Exacerbations• Diagnosis – 10% or more decline in pulmonary function testing – Increased sputum production – New infiltrate on CXR – Fever/hypoxia – Weight loss
  • 29. Cystic Fibrosis Exacerbations (continued)• Hospitalizations• Systemic antibiotics (culture directed)• Increased chest physiotherapy• Sinus surgery• Enhance nutrition• Psychosocial issues• End stage evaluate for lung/liver transplantation
  • 30. Test Results of Cystic Fibrosis Patient (age 15)
  • 31. Test Results of Cystic Fibrosis Patient (age 16)
  • 32. Test Results of Cystic Fibrosis Patient (age 22)
  • 33. Cystic Fibrosis Exacerbation with Pneumonia
  • 34. Bronchiectasis
  • 35. Bronchiectasis
  • 36. Outcomes• Decline in lung function associated with poorer nutritional status.• Decline in lung function has improved with early diagnosis and new therapies over the past two decades.• Median predicated survival has increased over the past two decades.• Increase in lung transplants in patients with end- stage cystic fibrosis pulmonary disease.
  • 37. FEV1 Percent Predicted vs. BMI in Adults (20-40 years by gender) http://www.cff.org/UploadedFiles/research/ClinicalResearch/2008-Patient-Registry-Report.pdf Accessed on 11/10/10
  • 38. Outcomes• Decline in lung function associated with poorer nutritional status.• Decline in lung function has improved with early diagnosis and new therapies over the past two decades.• Median predicated survival has increased over the past two decades.• Increase in lung transplants in patients with end- stage cystic fibrosis pulmonary disease.
  • 39. Median Percent Predicted FEV1 vs. Age (1990 and 2008) http://www.cff.org/UploadedFiles/research/ClinicalResearch/2008-Patient-Registry-Report.pdf Accessed on 11/10/10
  • 40. Outcomes• Decline in lung function associated with poorer nutritional status.• Decline in lung function has improved with early diagnosis and new therapies over the past two decades.• Median predicated survival has increased over the past two decades.• Increase in lung transplants in patients with end- stage cystic fibrosis pulmonary disease.
  • 41. Median Predicted Survivalhttp://www.cff.org/UploadedFiles/research/ClinicalResearch/2008-Patient-Registry-Report.pdf Accessed on 11/10/10
  • 42. Outcomes• Decline in lung function associated with poorer nutritional status.• Decline in lung function has improved with early diagnosis and new therapies over the past two decades.• Median predicated survival has increased over the past two decades.• Increase in lung transplants in patients with end-stage cystic fibrosis pulmonary disease.
  • 43. Cystic Fibrosis Lung Transplants (1990 – 2008) http://www.cff.org/UploadedFiles/research/ClinicalResearch/2008-Patient-Registry-Report.pdf Accessed on 11/10/10
  • 44. Research• Gene therapy• CFTR modulation• Restore airway surface liquid• Mucus alteration• Anti-inflammatory• Anti-infective• Lung transplantation• Nutrition
  • 45. Conclusion• Cystic fibrosis is the most common lethal genetic disease in Caucasians.• Underlying problem uniquely associated with abnormal CFTR protein function.• Increased viscosity of airway secretions causes progressive loss of lung parenchyma and function.• Improved nutritional status associated with better lung function.• Research has and will continue to provide new therapies and interventions to increase longevity.
  • 46. Q&AThank you for attending!